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Abstract 
The influence of microbial factors on adverse perinatal outcomes has become the focal point of recent 
investigations, with particular interest in the role of the microbiome and probiotic interventions. The purpose of 
this scoping review was to identify and critique the most recent evidence about these factors as they relate to 
pregnancies complicated by preeclampsia (PEC), preterm birth (PTB), and gestational diabetes mellitus (GDM). 
Four databases (PubMed, EMBASE, Web of Science, and Cochrane) were searched for articles published in 
English in the last 10 years with the concepts of the microbiome, probiotics, and PEC, PTB, or GDM. Forty-nine 
articles were eligible for full-text review. Five articles were excluded, leaving 44 articles that met all the eligibility 
criteria. The relationships between the microbiome and the risk for PEC, PTB, and GDM are not fully elucidated, 
although probiotic interventions seem beneficial in decreasing PEC and GDM risk. Probiotic interventions 
targeting bacterial vaginosis and elimination of infection in women at risk for PTB appear to be beneficial. More 
research is needed to understand the contributions of the microbiome to adverse perinatal outcomes. Probiotic 
interventions appear to be effective in reducing risk for select outcomes. 
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Introduction 
Pregnancy is characterized by a variety of microbiological, immunologic, and inflammatory changes that 
promote the health of both the mother and the developing fetus.1,2 The microbiome composition of the 
maternal gut changes dramatically between the first and third trimesters of pregnancy. These changes include 
increased β-diversity (differences between pregnant women), an overall increase in proteobacteria and 
actinobacteria, and reduced richness (lower number of species).3 Similarly, the vaginal microbiome composition 
changes substantially during the course of normal pregnancy. Diversity decreases, stability increases, and the 
vagina is enriched with Lactobacillus species.4 Vaginal pH becomes more acidic, while vaginal secretions are 
increased. However, by the third trimester, the vaginal microbiota resembles that of the nonpregnant state.4 
 
Host microbial interactions between the mother and the infant during pregnancy and the timing of the first 
exposure of the fetus to maternal microbes are not fully understood, although the largest exposure is thought to 
occur at birth.5 Historically, the intrauterine environment was thought to be germ-free; however, newer 
evidence suggests that a bacterial milieu may be present in the fetoplacental circuit.4,6,7 Microbial exposures and 
alterations have been implicated in the etiology of several adverse perinatal outcomes, including preeclampsia 
(PEC), preterm birth (PTB), and gestational diabetes mellitus (GDM).8,9 Recent investigations exploring the 
contributions of the human microbiome (defined as the total collection of microbes and their genetic 
characteristics)10 have become the focus of recent scientific inquiry in understanding the etiologic mechanisms 
of these obstetrical syndromes.11–13 
Background 
Completed in 2012, the Human Microbiome Project characterized microbial communities and their respective 
physiologic activities in a variety of body sites, including the nasal passages, oral cavity, urogenital system, and 
gastrointestinal tract.14 The initiative generated health reference data for a variety of microbiome sites, 
including those associated with normal pregnancy.3,4 Utilizing advanced molecular genetics and genomics 
technology, a variety of DNA-sequencing technologies including 16S (gene)-based analysis, as well as whole 
genome shotgun sequencing (entire bacterial DNA sequence of an organism), have allowed for both 
characterization of the types of microbes present in select body sites, as well as their genetic coding patterns 
and metabolic capacity.15,16 Advances in genomic analyses and the development of bioinformatics 
communication channels, such as Quantitative Insights into Microbial Ecology and Mothur (a microbiome 
software platform), have streamlined the process of sharing the taxonomic information identified in these 
analyses.17,18 Furthermore, these bioinformatic resources provide detailed information about the composition of 
body sites and the influence on host physiology, which are key in understanding health outcomes. 
 
The closely related area of microbial interventions has received considerable attention worldwide. Probiotic 
interventions contain live, usually freeze-dried bacterial microbes, often from the Lactobacillus and/or 
Bifidobacterium genera.19 When given in sufficient quantities, probiotic bacteria confer health benefits on the 
host.20 Probiotics are considered food. For use in antenatal applications, probiotic interventions can be 
administered either orally or vaginally. In most studies involving pregnant women, the oral route was used.19 
Prebiotic interventions administered orally are not live bacteria but rather comprise indigestible food 
substances, such as dietary fibers, certain starches, and oligosaccharides that are selectively fermentable.21 
Prebiotics are food for the probiotic bacteria and therefore increase microbial numbers. Synbiotics are a 
combination of probiotic and prebiotic interventions.22 Synbiotics produce beneficial effects by promoting the 
survival of the live microbes in the gut by stimulating growth and/or metabolic activity of one or more probiotic 
bacteria. Probiotic interventions and, to a lesser extent, prebiotics have been applied during pregnancy to 
improve maternal and fetal outcomes.19 More recently, synbiotic antenatal interventions have been studied.23,24 
 
The purpose of this scoping review is to explore and synthesize the scientific evidence about the maternal and 
neonatal consequences of microbial dysbiosis, with a focus on the role of the microbiome during pregnancy, as 
well as the influence of prebiotic and probiotic exposures. Specifically, this review outlines the most recent 
literature on perinatal microbiome and probiotics, prebiotics, and synbiotics specific to the maternal and 
neonatal outcomes in pregnancies that are complicated by PEC, PTB, or GDM. A brief review of the implications 
for the neonate as well as future clinical and research implications is discussed. 
Methods 
A comprehensive literature search of 4 databases (PubMed, EMBASE.com, Web of Science Core Collection, and 
the Cochrane Database of Systematic Reviews) was undertaken to identify relevant articles. A scoping review 
strategy was chosen as the review method, as research studies investigating the impact of microbiome and 
probiotics on adverse perinatal outcomes have not been comprehensively explored.25 To ensure that the full 
breadth and depth of the literature were explored, the searches were developed and conducted by an 
experienced medical librarian with input from the research team. This review was conducted using the 
standards established by the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) 
guidelines, which advocate for systematic and reproducible methods. Search strategy details are provided in 
Table 1. The results were exported to Endnote and reviewed by the clinical authors. 
 
Table 1. PubMed.gov search strategiesa 
Preeclampsia  ((("microbiota"[MeSH Terms] OR "microbiota"[tiab] OR "microbiome"[tiab] OR pre-
biotic[tiab] OR pre-biotics[tiab] OR "prebiotics"[MeSH Terms] OR "prebiotics"[tiab] OR 
"prebiotic"[tiab] OR "probiotics"[MeSH Terms] OR "probiotics"[tiab] OR "probiotic"[tiab]) 
AND (preeclampsia[tiab] OR pre-eclampsia[tiab] OR "Pre-Eclampsia"[Mesh])) AND 
("2008/08/10"[PDAT] : "2018/08/10" [PDAT]) AND english[All Fields]) 
Preterm birth  ((("microbiota"[MeSH Terms] OR "microbiota"[tiab] OR "microbiome"[tiab] OR pre-
biotic[tiab] OR pre-biotics[tiab] OR "prebiotics"[MeSH Terms] OR "prebiotics"[tiab] OR 
"prebiotic"[tiab] OR "probiotics"[MeSH Terms] OR "probiotics"[tiab] OR "probiotic"[tiab]) 
AND ("Premature Birth"[Mesh Terms] OR “premature birth"[tiab] OR “preterm birth"[tiab] 
OR “pre-term birth"[tiab])) AND ("2008/08/10"[PDAT] : "2018/08/10"[PDAT]) AND 
english[All Fields])  
Gestational 
diabetes 
mellitus 
((("microbiota"[MeSH Terms] OR "microbiota"[tiab] OR "microbiome"[tiab] OR pre-
biotic[tiab] OR pre-biotics[tiab] OR "prebiotics"[MeSH Terms] OR "prebiotics"[tiab] OR 
"prebiotic"[tiab] OR "probiotics"[MeSH Terms] OR "probiotics"[tiab] OR "probiotic"[tiab]) 
AND ("Diabetes, Gestational"[Mesh] OR “gestational diabetes”[tiab])) AND 
("2008/08/10"[PDAT] : "2018/08/10"[PDAT]) AND english[All Fields]) 
Data searched August 10, 2018, Chrome browser. 
 
Articles were included if published in English between January 1, 2008, and August 10, 2018, to capture the 
most recent evidence in line with the Human Microbiome Project that launched in 2008. The searches combined 
controlled vocabulary supplemented with key words related to the concepts of the microbiome (eg, microbiota, 
prebiotics, probiotics, synbiotics); PEC (eg, preeclampsia, eclampsia); GDM (eg, pregnancy, diabetes mellitus); 
and PTB (eg, preterm birth, premature birth). Gray literature (eg, scholarly but not commercially published 
documents such as conference abstracts or proceedings, government reports, white papers, and theses) was not 
included. 
 
Following the database searches, articles were selected if they met the inclusion criteria: (a) reported findings 
about PEC, GDM, or PTB AND; (b) reported outcomes of prebiotic and probiotic interventions; or (c) evaluated 
the composition of the maternal microbiome. Article quality was not assessed, but rather the types of studies 
were categorized to offer the most comprehensive review of the state of the science on the topics. The articles 
included in this scoping review were limited to level 1 experimental designs (randomized controlled trials [RCTs] 
or systematic reviews of RCTs); level 2 quasi-experimental designs; level 3 observational analytic designs 
(systematic review of cohort study, cohort study with control group, case-control study); and level 4 
(observational descriptive and cross-sectional studies).26 Titles and abstracts were initially reviewed to 
determine first round inclusion; full text was later reviewed for final decisions about inclusions. Articles were 
excluded if not directly related to the select perinatal outcomes (PEC, GDM, PTB), or if the study did not clearly 
measure the microbiome, prebiotic, probiotic, or symbiotic-related concepts. The PRISMA flow diagram is 
presented in Figure 1. A series of tables are used to present the literature. Table 2 contains the systematic 
reviews and meta-analyses.28–36Table 3 presents the findings of individual trials: RCTs, prospective cohort 
studies, retrospective cohort studies, and a case-control study.23,24,37–50 Studies of the microbiome and the 
perinatal outcomes of PEC, GDM, and PTB are presented in Table 4.12,51–67 
 
 
Figure 1. PRISMA 2009 flow diagram. For more information, visit www.prisma-statement.org. From Moher et 
al.27  
Table 2. Systematic review and meta-analyses 
     Findings related to 
intervention if applicable 
 
Author (year) Systematic 
review 
Meta-
analysis 
Articles 
included 
Intervention if 
applicable 
Significant Nonsignificant of (NA) statistics 
not provided 
Preeclampsia (PEC)       
Lindsay et al28 (2013)a x  7 Probiotics ↓ preeclampsia (OR = 0.80, 
95% Cl: 0.66-0.96) and severe 
preeclampsia (OR = 0.61, 
95% Cl: 0.43-0.89) 
NA: ↓preeclampsia 
Gestational diabetes 
mellitus (GDM) 
      
Barrett et al29 (2014) x  1 Probiotics ↓ diagnosis of GDM (P = .03)  
Dallanora et al30 
(2018) 
x  7 Probiotics  NA: Probiotics may improve 
glycemic control, ↓ VLD 
Cholesterol, ↓ inflammatory 
marker 
Lindsay et al28 (2013) x  7 Probiotics  NA: ↓ fasting blood glucose, 
incidence of GDM 
Pan et al31 (2017) x x 6 Probiotics ↓ fasting serum insulin (P = 
.00001), HOMA (P = .02) 
FBS (P = .9), gestational age (P = 
.63), birth weight (P = .9) 
Taylor et al32 (2017) x x 4 Probiotic ↓ HOMA (P = .01) FBS (P = .96), LDL-cholesterol (P = 
.67), weight gain, mode of birth, 
neonatal outcomes, adverse events 
(P levels not reported) 
Zheng et al33 (2018)  x 10 Probiotics ↓ fasting serum insulin (P = 
.0001), HOMA (P = .03) 
FBS (P = .26), lipid levels (P = .71), 
HDL cholesterol (P = .87), LDL 
cholesterol (P = .97), triglycerides 
(0.29) 
Spontaneous 
premature labor (sPTL) 
and/or premature 
birth (sPTB) 
      
Jarde et al34 (2018) x x 49 Probiotic 
Prebiotic 
 PTL <34 wk (P = .96), or <37 wk (P = 
.96); PTL <37 wk (P = .73), or <37 
wk (P = .83) 
Mendz et al35 (2013) x  13 N/A ↓ genital infection with 
probiotics (P = .00096) 
NA: Vaginal bacteria were the most 
common source of intra-amniotic 
infection 
Othman et al36 (2007) X x 3 Probiotics  PTB <32 wk (P = .79), PTB <37 wk (P 
= .26) 
Abbreviations: CI, confidence interval; FBS, fasting blood sugar; HDL, high-density lipoprotein; HOMA, homeostatic model assessment for insulin 
resistance; LDL, low-density lipoprotein; OR, odds ratio; VLD, very low density. 
a Same systematic review noted later. 
 
Table 3. Summary of probiotics studies 
     Findings related to 
intervention 
 
Author (year) Study design Total 
participants 
Sample and 
microbial 
intervention a 
Purpose Significant Nonsignificant 
Dolatkhah et al40 
(2015) 
RCT  64-GDM  32-Probiotic 
32-Placebo 
Glucose 
metabolism 
Weight gain 
↓pregnancy weight 
gain study weeks 5 
and 6(P < .05), FBS (P 
< .05), insulin 
resistance index (P < 
.05) 
Pregnancy weight gain (study 
weeks 1-4) 
Hajifaraji et al41 
(2018) 
RCT  GDM  Probiotic 
Inflammation 
Oxidative stress   
Jafarnejad et al42 
(2016) 
RCT  82-GDM  41-Probiotic 
41-Placebo  
Glycemic 
control 
Inflammatory 
status 
↓IL-6 (P = .04), TNF-α 
(P = .04), hs-CRP (P = 
.03) 
FBS, HbA1c, HOMA, IL-10, insulin 
levels 
Karamaliet al43 
(2016) 
RCT  60-GDM  30-Probiotic 
30-Placebo 
Glycemic 
control 
Lipid profiles 
↓FBS (P < .001), 
serum insulin levels (P 
< .001), HOMA (P = 
.03), insulin sensitivity 
(P < .0007), 
triglycerides (P = .03), 
VLD cholesterol (P = 
.03) 
Lipid profiles 
Kijmanawat et al44 
(2018) 
RCT  60-GDM  28-Probiotic 
29- Placebo 
Insulin 
Resistance 
↓FBS (P = .34), 
fasting plasma insulin 
(P = .001), HOMA (P 
= .001)  
Pregnancy weight gain 
Lindsay et al45 
(2015) 
RCT  149-GDM  74-Probiotic 
75 Placebo  
Metabolic 
health  
↓Total cholesterol (P 
= .031), LDL 
cholesterol (P = .011)  
FBS (P = .588), insulin (P = 
.927), HOMA (P = .875), C-
peptide (P = .843), HDL 
cholesterol (P = .341), 
triglycerides (P = .687), HDL 
ratio (P = .704), LDL ratio (P = 
.244) 
Luoto et al46 
(2010) 
 
RCT  256 gravidas  67-Probiotic 
and dietary 
intervention 
63-Placebo 
and dietary 
intervention 
85-Control and 
placebo  
Pregnancy 
outcome and 
prenatal and 
postnatal 
growth  
Probiotic plus dietary 
intervention ↓GDM 
(P = .003) 
 
Nabhani et al23 
(2018) 
RCT 90-GDM  48-Synbiotic 
49-Placebo  
Insulin 
resistance 
Lipid profile 
Total 
antioxidant 
capacity 
The symbiotic 
intervention resulted 
in decreased LDLs 
from baseline (P < 
.05). ↓ SBP and DBP 
in symbiotic group 
compared with 
placebo (P < .05). 
FBS, insulin 
resistance/sensitivity, lipid 
profile, TAC indices symbiotic 
group compared with placebo (P 
< .05). 
Wickens et al47 
(2017) 
RCT  Healthy 
pregnant 
women 
212-Probiotic 
211-Placebo  
GDM prevalence  ↓GDM in women 
aged ≥35 y(P = .009) 
and women with 
history of  GDM (P = 
.004)  
Overall GDM prevalence (P = 
.08) 
Spontaneous 
premature labor 
(sPTL) and/or 
spontaneous 
premature birth 
(sPTB) 
      
Kirihara et al48 
(2018) 
 
Retrospective 
cohort  
121  45-Probiotic 
76-Controls  
Perinatal 
outcomes sPTB 
 
↑Gestation age (P = 
.012), ↓sPTB <32 wk 
(P = .001), ↓CAM (P = 
.03), ↓vaginal 
Lactobacillus (P = .052)  
Funisitis (P = .052), birth weight 
(P = .021) 
Krauss-Silva et al49 
(2011) 
 
RCT  644 
asymptomatic 
gravidas 
320-Probiotic 
324-Placebo  
 
Prevention of 
PTB-associated 
BV 
 
 Preliminary results: sPTD <34 wk 
(P = .31), sPTD <37 wk (P = .14) 
Myhre et al50 
(2011)  
Prospective 
cohort study  
23 822 healthy 
gravidas  
950-Probiotic 
milk 
17 938-
controls 
sPTB risk  ↓sPTB with high 
intake or probiotic 
milk (P < .035) 
 
Nordqvist et al39 
(2018) 
Prospective 
cohort  
37 050 
Norwegian 
women  
Probiotic milk  Intervention 
timing and 
incidence of PTL  
Probiotic milk intake 
during early 
pregnancy intake  
↓PTL (P = .03)  
Dose response 
 
  
Table 4. Summary Table of microbiome studies, often metagenomic-based 
Author, year Study design Total 
participation 
Microbiome 
site studied 
Findings 
Preeclampsia     
DiGiulio et al51 
(2010)  
Retrospective 
cohort  
62  Intra-amniotic  Women with PEC with MIAC 
demonstrated a ↑ mean amniotic 
fluid IL-6 level (P = .002). 
Jaramillo et 
al52 (2012)  
 
Secondary 
analysis of RCT  
 
57  
 
Oral 
 
RCT was on subgingival scaling and 
planning vs supragingival 
prophylaxis 
No differences in periodontopathic 
organisms between the 2 groups. 
Amarasekara 
et al12 (2015)  
 
Nested case-
control  
 
110: 
55 cases, 
55 controls  
Placenta  12.7% of the placenta samples of 
women with PEC were PCR positive 
for the 16S rRNA gene. Pathogenic 
microbiome identified: Listeria, 
Salmonella, and Escherichia. 
Nizyaeva et 
al53 (2017)  
Case-control  32: 
20 cases, 
12 controls  
 
Placenta  25% of the PEC group demonstrated 
pathologic microbial growth 
Control group placentas were 
culture negative.  
Placental microbes were identified 
only in women with PEC who 
delivered after 34 wk of gestation 
Liu et al54 
(2017) 
Case-control  100: 
26 first trimester 
24 second 
trimester 
24 third 
trimester 
26 controls 
 
Gut  Women with PEC: there was an 
overall ↑ in pathogenic bacteria. 
Clostridium perfringens (P = .03) and 
Bulleidia moorei 
(P = .00) ↑ in women with PEC 
decrease noted in the probiotic 
bacteria Coprococcus catus (P = .03). 
Gestational 
diabetes 
    
Crusell et al55 
(2018) 
Prospective 
cohort 
50 GDM, 157 
controls 
Gut  GDM associated with significant gut 
microflora disruption similar to that 
found in nonpregnant adults with 
type 2 diabetes 
Kuang et al56 
(2017)  
 
Exploratory 
descriptive  
124: 43 GDM, 81 
healthy 
Stool in 
second 
trimester 
Significant differences in 
microbiomes of women with or 
without GDM. ↓ diversity noted 
with GDM women. 
Wang et al57 
(2018)  
Descriptive  346 women with 
GDM and 140 of 
their NBs to total 
of 581 women, 
248 NBs = 1062 
samples  
Oral, pharynx, 
GI, vagina, 
meconium, 
amniotic fluid  
Lactobacillus iners strains were 
significantly greater in those with 
GDM (P< .05). 
Also ↑ viral load in meconium of 
NBs whose mothers have GDM.  
Microbial variations showed 
convergence across body sites with 
more similar community structure in 
those with GDM.  
Zheng et al58 
(2013) 
Descriptive 
comparison 
105, in 4 groups: 
HP = 31, GDM = 
39, T1DM = 
35, HN = 32 
 
Vagina, for 
fungal flora  
 
Fasting plasma glucose (FPG), 1- and 
2-h plasma glucose levels, & HbA1c 
were always ↑ in GDM and type 1 
DM groups (P < .01).  
Diversity in fungi greater by 
pregnancy group, ↑ from 13, 17, 
and 20 species respectively, in HP, 
GDM, and TIDM groups 
Preterm birth     
Ardissone et 
al59 (2014)  
Descriptive  52 infants: (23-41 
wk at birth) 
Meconium  
 
Gestational age prior to 33 wk at 
birth had largest influence on 
microbial community structure (P = 
.029); mode of delivery (C/Sec vs 
vaginal) also had effect (P = .044).  
Associated bacteria seen in PTBs: 
Enterobacter, Enterococcus, 
Lactobacillus, Photorhabdus, and 
Tannerella 
Avershina  et 
al60 (2017) 
From RCT 
(about allergy 
prevention)  
335: 
256 at 36 wk, 
105 in labor 
Vagina  Swabs at 36 wk or labor admission: 
at labor onset had ↑ α-diversity and 
↑ closer to labor. 
Brown et al61 
(2018) 
Prospective 
cohort  
250 women with 
history of early 
loss 
Vagina  In those with PTBs (38/250 = 15%) 
compared with term births, 
Lactobacillus was depleted prior to 
PPROM (P = .026), which occurred 
at mean gestational age of 30 wk, 
and depletion persisted after 
PPROM (P = .005). Dysbiosis also 
occurred in women with high 
amounts of Lactobacillus when 
treated with erythromycin (P = 
.00009), as did NB sepsis. 
Dahl et al62 
(2017)  
Prospective 
cohort, case 
control  
121 births: 102 
term, 19 = PTB 
Stool at 4 d 
postpartum  
If PTBs, had lower α-diversity in gut 
and significantly fewer OTUs in 
genera of Bifidobacterium and 
Streptococcus and families in 
Clostridiales order (stats not 
available). 
Doyle et al63 
(2014) 
. 
Cross-sectional 
study  
 
989 258 (26.1%) 
with chorio, 120 
(12.1%) had 
severe  
Placenta  
 
Nonsevere chorioamnionitis 
(defined as ≥25 neutrophils 
granulocytes on average per 10 high 
power field) showed difference in 
community members, ↑ bacterial 
load, higher phylogenetic diversity, 
↓ species richness, and smaller 
(shorter) newborns 
Hyman et al64 
(2014)  
Prospective 
cohort  
88: 
17 PTBs, 
71 term births 
Vagina  Significant correlation between 
race/ethnicity and diversity (used 
Shannon Diversity Index). 
Location of sampling matters (prefer 
posterior fornix). Small sample size 
with limited statistical analysis. 
Subramaniam 
et al65 (2016)  
Retrospective, 
stratified by 
race, BV, and 
PTB  
40 prior taken 
vaginal swabs at 
21–25 wk, and 
Nugent smears  
Vagina  BV samples had greater diversity (P 
< .05), with more abundant BV-
associated bacteria.  
Underpowered to compare PTB with 
microbiome but may be that 
changes in communities are linked 
to sPTBs rather than specific 
organisms. 
Tabatabaei 
et al66 (2018)  
Nested case-
control in 
cohort  
450: 
17 early 
SPTBs,  
77 late SPTBs, 
and 356 
controls  
Vagina  
 
↑ diversity (P < .05) in CST IV. 
Presence of BV-associated 
bacteria (Gardnerella vaginalis, 
Atopobium vaginae, and 
Veillonellaceae bacterium) also 
associated with PTB 
Wylie et al67 
(2018) 
Nested case-
control in 
prospective 
cohort study  
60: 
128 swabs 
through PG 
Vagina for 
virome 
24 had PTBs (38.7%). African 
American women were 65% of 
sample.  
Higher viral richness was 
associated w/ PTB in total 
sample (P = .0005) and African 
American subgroup (P = 
.0003). Both high diversity of 
bacteria and viruses in first 
trimester were associated with 
↑ risk for sPTB (P = .01); l ↓ 
combined diversity with term 
birth (P < .0001). 
Abbreviations: CST IV, community state type 4; GDM, gestational diabetes mellitus; HN, healthy nonpregnant; 
HP, healthy pregnant; IL, interleukin; MIAC, microbial invasion of the amniotic cavity; NB, newborn; OTUs, 
operational taxonomic units are clustered, grouped sequences; PCR, polymerase chain reaction; PEC, 
preeclampsia; PG, pregnancy; PPROM, preterm premature rupture of membraines; PTB, preterm birth; PTL, 
preterm labor; RCT, randomized controlled trial; sPTB, spontaneous preterm birth; T1DM, type 1 diabetes 
mellitus. 
 
A total of 1264 articles were identified through the database searches. Duplicates (396) were excluded leaving 
868 articles to be screened in the initial abstract-screening phase. Forty-nine were eligible for full-text review. 
Five articles were excluded during the full-text review phase, leaving 44 articles that met all the eligibility criteria 
for inclusion in this study. In the following sections, the most recent evidence related to PEC, GDM, and PTB will 
be presented. Details of the types and dosages of prebiotic, probiotic, and synbiotic interventions are beyond 
the scope of this review but can be found in the individual studies. 
Results 
The role of the microbiome in PEC 
Preeclampsia is a multisystem pregnancy complication characterized by new-onset hypertension with 
proteinuria, or evidence of systemic disease primarily in the liver and kidneys, with onset after 20 weeks of 
gestation.68 The etiologic pathways of PEC are multifactorial and include maternal and fetal factors; however, 
the full pathway is not fully elucidated. The disorder is characterized by impaired vascular function and 
activation of maternal systemic inflammation in several organs, which can be aggravated by many factors, 
including infection. Studies have shown that women with asymptomatic bacteriuria, urinary tract infection, 
periodontal disease, and chronic pyelonephritis are at increased risk for PEC.51,69 As such, the current focus of 
scientific inquiry has shifted to learning more about the role of the microbiome in the multifactorial pathway of 
PEC. 
 
One of the focal areas in recent microbiome studies of PEC is vascular dysfunction in the placenta, which has 
been implicated as one of the leading pathways underpinning the disorder.68 In a nested case-control study, 
researchers compared the placental tissue of women with PEC with normotensive women to screen the samples 
for the presence of bacteria. Using polymerase chain reaction and next-generation sequencing methods, the 
researchers found that 12.7% of the placenta samples of women with PEC were polymerase chain reaction 
positive for the 16S rRNA gene. The microbiome of the samples identified a variety of commensal and 
pathogenic bacteria, including Listeria, Salmonella, and Escherichia.12 Similarly, Nizyaeva et al53 explored the 
differences in the histological and microbial features of PEC in a nested case-control study. The sample included 
20 reproductive age women with the disorder and 12 normal controls, all of whom were between 26 and 39 
weeks of gestation.53 Forty-five percent of the women with PEC demonstrated chronic villitis (P < .05) as 
compared with the control group at 8%. All placentas were cultured; 25% of the PEC group demonstrated 
pathologic microbial growth (including Streptococcus agalactiae or group B Streptococcus and Staphylococcus 
warneri), while all the control group placentas were culture negative. Placental microbes were identified only in 
women with PEC who delivered after 34 weeks of gestation, suggesting that microbial pathways may be 
particularly important to consider in women during later pregnancy. Together, these study findings suggest that 
microorganisms may contribute to an inflammatory response and support the role of microbial interactions in 
the etiologic pathway of PEC. 
 
Infection and inflammation have also been implicated in the complex pathway of PEC,69,70 with some focus on 
the influence of microbes within the intrauterine cavity. In a retrospective cohort investigation, DiGiulio et al51 
found that women with PEC who had microbial invasion of the amniotic cavity demonstrated a higher mean 
amniotic fluid IL-6 level (P = .002). The prevalence of microbial invasion overall in women with PEC was found to 
be low, although 3 of the 6 women with microbial invasion were positive for Sneathia/Leptotrichia spp,51 which 
are microbiota associated with bacterial vaginosis (BV) and isolated cases of maternal bacteremia and fetal 
demise.71,72 Although microbial invasion of the intra-amniotic environment has been identified in women with 
PEC, more studies are needed to elucidate the pathways by which microbes influence the intrauterine 
physiology. 
 
The association between maternal periodontal disease and PEC risk was explored in 2 studies, a meta-analysis70 
and a secondary analysis of an RCT.52 In a recent meta-analysis of 11 observational studies including 1118 
women with PEC compared with 2798 women, researchers found that women with periodontal disease before 
32 weeks of gestation had a 3.6-fold increased risk of PEC (odd ratio [OR] = 3.69; 95% confidence interval [CI] = 
2.58-5.27) compared with women without gum disease.70 The risk was also increased if periodontal disease was 
present 48 hours prior to delivery (OR = 2.68, 95% CI = 1.39-5.18), as well as within 5 days after delivery (OR = 
2.22; 95% CI = 1.16-4.27). In a secondary analysis of an RCT conducted by Jaramillo et al,52 the subgingival 
microbiota of 57 women with mild PEC were evaluated for differences related to a periodontal intervention 
(subgingival scaling and planing vs supragingival prophylaxis). There were no differences found in reduction of 
periodontopathic organisms between the 2 groups.52 Despite these findings, the relationship between the oral 
microbiome and PEC risk remains hypothetical, as most of the current literature consists of proposed pathways 
related to hematogenous spread of microbial pathogens from the oral environment.1,73–76 A variety of oral 
microbial pathogens have been implicated in the etiology of PEC in previous studies, but not enough evidence 
has been identified to support a causal link.77 More research is needed to determine whether there is an 
association between the oral microbiome and PEC risk. 
 
Preeclampsia has features similar to metabolic syndrome, as women with this condition often develop altered 
glucose and lipid metabolism, insulin resistance, and endothelial damage.78 Given the role of the gut microbiota 
in metabolism, a recent study by Liu et al54 evaluated the gut microbiome of women with PEC to determine 
whether intestinal dysbiosis could be detected as a marker. One hundred women were grouped into 4 
categories: 26 women with PEC and 3 healthy control groups in the first, second, and third trimesters of 
pregnancy. The dominant bacterium present in all samples was Bacteroidetes; however, in PEC women there 
was an overall increase in pathogenic bacteria. Specifically, Clostridium perfringens (P = .03) and Bulleidia moorei 
(P = .00) increased in women with PEC, with a decrease noted in the probiotic bacteria Coprococcus catus (P = 
.03). These findings suggest that there may be a shift in the gut microbial composition in women with PEC. 
 
Overall, 5 groups of investigators studied the microbiome of PEC.12,51–54 In 2 studies, the placenta site was 
analyzed12,53; in the remaining 3, the mouth,52 gut,54 or an intra-amniotic51 site was examined. Some findings 
supported the association between pathogenic bacteria and PEC, but this was not a consistent finding. 
Furthermore, specific pathogenic organisms were not identified in common between the studies on PEC. 
 
Probiotic use and PEC 
The pathophysiologic pathways underpinning PEC are complex and not fully elucidated; however, maternal 
immune system dysregulation and infections were associated with PEC risk and severity.79 Probiotics are 
thought to reduce both systemic and placental inflammation, thus reducing PEC risk.37 Probiotics such as 
Lactobacillus acidophilus and L rhamnosus were shown to influence gene regulatory pathways and expression in 
immune response pathways of the human gut mucosal lining,80 further supporting the exploration of probiotics 
as an intervention to delay and reduce the incidence of PEC. 
 
Several studies investigating the association between probiotic products and PEC suggest a beneficial effect of 
probiotics in reducing PEC risk.28,37,39 A large prospective Norwegian Mother and Child Cohort Study was 
conducted from 1999 to 2009 and included data from 108 000 pregnancies. Using these data, Brantsaeter et al37 
conducted a prospective cohort study of the relationship between probiotic ingestion in early pregnancy and the 
risk of PEC in a sample of 33 399 primigravidas.37 In Norway, there are 2 main probiotic milk products that are 
consumed. The probiotic beverages deliver 108 probiotic bacteria per milliliter. Therefore, the authors calculated 
the probiotic dose based on dietary recall of these standard products. The researchers categorized dietary 
probiotic ingestion as follows: none, low, moderate, and high. Just more than 5% (1755 women) developed PEC. 
High-level probiotic intake (median = 200 mL/d with daily ingestion or greater) was associated with a significant 
reduction in all PEC (OR = 0.80, 95% CI: 0.66-0.96) and severe PEC (OR = 0.61, 95% CI: 0.43-0.89). These findings 
were also reported in a systematic review by Lindsay et al,28 who explored the use of probiotics during 
pregnancy with maternal outcomes, including PEC. Seven articles were identified in the review, although only 1 
study was identified related to PEC risk. Nordqvist et al39 conducted a secondary analysis of the Norwegian 
Mother and Child Cohort Study to explore probiotic intervention timing. Specifically, they analyzed probiotic 
milk intake before pregnancy, during early pregnancy, and during late pregnancy, with PEC risk in nulliparous 
women (n = 37 050). The researchers found that probiotic milk intake in late pregnancy, but not before or during 
early pregnancy, was associated with lower PEC risk (OR = 0.80, 95% CI: 0.68-0.94).39 Together, these studies 
suggest that probiotic intake was associated with reduced PEC risk. 
 
While the etiology of PEC remains unclear, the markers of hypoxia, oxidative stress, and hemolytic pathways, 
including hemolysis, elevated liver enzymes, and low platelets, have been observed in women with PEC.81 
Therefore, the physiologic consequences of PEC extend beyond the maternal environment and contribute to 
fetal complications. A study by Ekambaram et al38 investigated the antihemolytic and antioxidant efficiency of 2 
probiotic yeasts (Monascus purpureus and Saccharomyces cerevisiae) on fetal cord blood red blood cells of 
infants born to PEC mothers as compared with healthy normotensive controls. The red blood cells of the PEC 
sample were found to have low antioxidant status (P < .05), increased oxidative stress, (P < .05), increased 
nitrative stress (P < .05), and increased hemolysis (P < .001). Oxidative stress hemolysis decreased in the cord 
blood red blood cells for both groups after incubation with both probiotic yeasts. Specifically, M purpureus 
resulted in significant reactive oxygen radical scavenging (removal) (P < .001), and S cerevisiae resulted in 
significant nitric oxide radical scavenging (removal) (P < .001). These findings hold promise that probiotics could 
modulate oxidative stress in offspring. 
 
The role of the microbiome in gestational diabetes mellitus 
The normal physiologic adaptations of pregnancy provide for the metabolic needs of the growing fetus. 
Gestational diabetes mellitus is defined as a carbohydrate intolerance with hyperglycemia with onset during 
pregnancy that varies in severity.82 Gestational diabetes mellitus is a heterogeneous group of metabolic 
disorders that impacts up to 14% of pregnancies.83 Between 20% and 50% of women with GDM will go on to be 
diagnosed with type 2 diabetes within 5 years.84 Evidence has emerged that highlights the link between the gut 
microbiome and metabolism. This has led researchers to hypothesize that the gut microbiome may impact 
gestational metabolism and development of GDM.56 The microorganisms that colonize the gut influence the 
metabolism of nutrients, hunger, satiety, and both lipid and glucose metabolism. Gestational diabetes mellitus 
has been associated with subclinical inflammation that may lead to oxidative stress.41 Therefore, efforts to 
prevent and treat GDM have included probiotic and/or dietary interventions. Outcomes studied include a 
variety of metabolic and inflammatory markers. 
 
Four groups of researchers examined the microbiome related to GDM.55–58 The sites cultured varied widely 
between studies; stool was cultured in 2 studies,55,56 vaginal swabs to examine fungi were used in 1 study,58 and 
in another study, both viruses and bacteria were examined from 3 sites in women (oral, gastrointestinal, and 
vagina) and 4 sites from their newborns (oral, pharynx, meconium, and amniotic fluid).57 Dysbiosis was identified 
more frequently in women with GDM, who also exhibited less overall microbial diversity.56 More pathogens 
were found in women with GDM, including more viruses and fungal species.57 The relationships between 
dysbiosis and GDM need to be more fully elucidated. 
 
Probiotic use and gestational diabetes mellitus 
Gestational diabetes mellitus probiotic and synbiotic interventions have been addressed in 9 RCTs and 7 
systematic reviews and/or meta-analyses. In 7 of the RCTs, participants were randomized after GDM diagnosis 
to probiotic or placebo groups.23,24,40,42–45 The effect of a probiotic intervention on inflammatory markers and 
oxidative stress in GDM was the goal of 1 study.41 Other outcomes attributable to the probiotic intervention are 
somewhat variable between RCTs. Both C-reactive protein and tumor necrosis factor were significantly 
decreased among probiotic group participants compared with placebo in 2 studies.41,42 Women in the probiotic 
intervention groups had lower rates of GDM than those taking placebos in 2 studies.46,47 Fasting blood glucose 
was significantly decreased in probiotic group participants in 3 RCTs.40,43,44 A review of the meta-
analyses/systematic reviews allowed more patterns to emerge. Two systematic reviews/meta-analyses have 
near-identical findings.31,33 Probiotic interventions resulted in a significant decrease in fasting serum insulin and 
HOMA model assessment for insulin resistance.29,31,33 Overall in the meta-analyses, outcomes related to lipids, 
gestational age, and inflammatory markers did not reach statistical significance. 
 
The role of microbiome in preterm birth 
During pregnancy, the vagina is dominated by Lactobacillus species and characterized by less richness and 
diversity, but more stability, than the nonpregnant vaginal microbiome.85 The bacteria of the vaginal 
microbiome have been classified into 5 community state types (CSTs).60,86 CST-I to CST-III and CST-V are 
characterized by high levels of specific species of Lactobacillus. Vaginal Lactobacilli species include L acidophilus, 
fermentum, crispatus, and jensenii.87 These Lactobacilli contribute to a protective biofilm on the vaginal 
mucosa.88 Some Lactobacillus species produce lactic acid that acidifies the vaginal mucosal surface and prevents 
the adherence of pathogens.89 Probiotic bacteria also secrete other substances that are associated with vaginal 
health (bacteriocins, vitamins, and cytokines).89 
 
At least 30% of premature labors are associated with maternal infection.36,85,90,91 Microbial pathogens can reach 
the uterine cavity through 3 routes that can lead to infection: (a) ascending from the vagina and cervix, (b) 
retrograde seeding from the abdominal cavity through the fallopian tubes, and (c) hematogenous seeding 
through the placenta.90 At the level of the maternal mucosal surface, some microorganisms secrete 
phospholipase A2 that acts on phospholipids to form arachidonic acid, which ultimately converts to 
prostaglandins (PG, PGE2, PGF2A). Other microorganisms secrete endotoxins that stimulate a cascade of 
proinflammatory cytokines.91 These microbial pathways work together to magnify the inflammatory response 
and contribute to the degradation of the collagen matrices of the cervix, fetal membranes, placenta, and 
uterus.91 
 
Among the studies reviewed, a number of studies were designed to examine the microbial aspects of these 
inflammatory pathways to predict PTB. Preterm birth is associated with higher α-diversity (intraindividual) of 
vaginal flora.64 The CST-IV60,86 is associated with BV and is characterized by mixed community types, enriched in 
various anaerobic bacteria, with low levels of Lactobacillus. Bacterial vaginosis is a microbial dysbiosis associated 
with a 40% increase in the risk of PTB.36 When BV occurs, there is a shift from a predominance of Lactobacilli 
populations to a higher proportion of other organisms: Gardnerella vaginalis, Prevotella bivia, Mobiluncus sp, 
Mycoplasma hominis, and Atopobium vaginae.86 This results in the characteristic vaginal secretions with a 
number of common clinical findings, including pH 5.5 or greater, presence of clue cells, and positive whiff test.92 
Therefore, probiotic interventions have been used to address the BV dysbiosis in an effort to reduce the risk of 
PTB. 
 
Nine groups of researchers examined the microbiome related to PTB.59–67 Three of the studies that examined 
PTB do not lend themselves to comparison because each investigative group sampled a different body site.59,62,63 
In the 6 studies60,61,64–67 that used vaginal microbial samples, all focused on BV-related assessments, including 
CST-IV categorization, the presence of BV-associated bacteria, and/or a decrease in Lactobacillus dominance. 
One study reported viruses present.67 In the systematic review by Mendz et al,35 the bacterial etiology of intra-
amniotic infections was examined. Vaginal organisms were responsible for most intra-amniotic infections.35 
 
In 3 investigations, race was explored as a possible factor in PTB, in relationship to the microbiome.64,65,67 Hyman 
et al64 reported that significant correlations were identified between race/ethnicity and diversity in the vaginal 
microbiome. Using the Shannon Diversity Index as the measure, African American women had the greatest 
diversity of microbes and Caucasians had the least (P = .003). Hispanics had the second most diverse vaginal 
microbiome (P = .0082) compared with Caucasians. Caucasian women who experienced PTB had greater 
microbial diversity than those who had term births (P = .00016).64 Wylie et al67 reported higher richness and 
diversity in the virome of women who experienced PTBs in the total sample (P = .0005) and those in the African 
American subgroup who had PTBs (P = .0003). For the entire sample, both high diversity of bacteria and viruses 
in the first trimester were associated with the highest risk for spontaneous PTB (P = .01), while lower combined 
diversity was associated with term birth (P < .0001). Subramaniam et al65 examined their small sample that was 
stratified by race and determined that the microbiota did not differ by racial groups. 
 
Probiotic use and preterm birth 
Because of the variation in premature labor diagnosis in most studies reviewed, PTBs (<37 weeks and/or <34 
weeks) were used as the primary study outcomes. Two systematic reviews and 4 clinical studies explored the 
efficacy of probiotic interventions to reduce PTB risk. Othman et al36 conducted a systematic review of probiotic 
interventions to prevent premature labor. Three studies met their inclusion criteria; the impact of probiotic 
interventions on vaginal infection was based on 2 trials including a total of 99 participants. The researchers 
found that probiotic use reduced the risk of genital infection by 81% (relative risk [RR]: 0.19; 95% CI: 0.08-0.48). 
However, they found insufficient evidence for utility of probiotic intervention for the prevention of premature 
labor. 
 
Using participants in the Norwegian Mother and Child Cohort Study prospective cohort study, Myhre et al50 
explored the relationship between the ingestion of probiotic containing yogurt products and premature labor, 
using a sample of 18 888 Norwegian women. Probiotic intake was calculated using dietary histories and 
operationally defined as low, average, or high. The average probiotic intake in the high group was 138.4 mL/d. 
Between 2002 and 2007, there were 950 cases of PTB of less than 37 weeks. Women with the “highest” intake 
of probiotic yogurt experienced significantly lower risk of PTB (P = .035; OR: 0.820; 95% CI: 0.681-0.986). 
 
Jarde et al34 conducted a systematic review of pregnancy outcomes in women taking probiotics or prebiotics. In 
2 meta-analyses, the authors found no evidence that probiotic interventions altered the incidence of PTB of less 
than 34 weeks (RR: 1.03, 95%, CI: 0.29-3.64, I2: 0%, 1017 women in 5 studies) or PTB of less than 37 weeks (RR: 
1.08, 95% CI: 0.71-1.63, I2: 0%, 2484 women in 11 studies). A significant limitation of these meta-analyses is the 
inclusion of studies of women from high-risk groups, such as obese women28 and those with GDM.28,42 The 
heterogeneity of the studies included in these meta-analyses makes interpretation of the findings difficult. For 
example, only 1 of the 11 studies in the meta-analyses aimed to reduce PTB using a probiotic intervention.49 
 
Krauss-Silva et al49 enrolled healthy pregnant women in an RCT using 2 Lactobacillus species (L rhamnosus GR-1 
and L reuteri RC-14) aimed at treating asymptomatic BV infections and ultimately PTB of less than 34 weeks of 
gestation. At the time of publication of preliminary findings, the study sample was insufficient to draw 
conclusions about intervention efficacy. More recently, Kirihara et al48 studied women at high risk for PTB in an 
RCT. Bacterial vaginosis was prophylactically treated with a probiotic combination product (S faecalis, 
Colstridium butyricum, and Bacillus mesentericus) versus a placebo from 12.5 ± 5 weeks until the time of birth. 
Findings demonstrated that women in the probiotics group had significantly less spontaneous PTB, increased 
gestational age, decreased intrauterine infections, and higher rates of normal vaginal flora. 
Discussion 
There was significant variation in the findings from studies investigating role of the microbiome during 
pregnancy, as well as the influence of prebiotic, probiotic, and synbiotic exposures in women with PEC, GDM, 
and PTB. Some findings supported the association between pathogenic bacteria and these perinatal outcomes, 
but this was not a consistent finding. Furthermore, specific pathogenic organisms were not identified in 
common between studies. Probiotic exposures appear to have a beneficial effect in decreasing PEC and GDM 
risk and also appear to decrease the risk for PTB via the reduction of vaginal infections such as BV. 
 
Preeclampsia 
The relationships between the microbiome, prebiotic, probiotic, or synbiotic use and the risk for PEC are not 
fully understood. However, the findings of this review suggest that more research is justified, given the findings 
that (a) placental tissues of women with PEC were found to harbor pathogenic microbes along with signs of 
placental inflammation and (b) probiotic use is associated with a reduction in PEC risk. Although there were a 
limited number of studies identified, the findings suggest that more research is needed to explore these 
biological mechanisms as viable pathways in the complex pathophysiologic pathway underpinning PEC. Future 
well-controlled RCTs to explore causal relationships between probiotic use and PEC risk are needed. 
 
It may be beneficial to explore the relationships between the microbiome, microbial interventions, and PEC 
incidence in high-risk groups. Considering the inflammatory state of obesity and the increased risk of 
hypertensive disorders of pregnancy among obese pregnant women, a recent study associated with an RCT 
(study of probiotics in GDM) explored whether select gut microbes and metabolites among obese pregnant 
women influenced gestational blood pressure. Overweight and obese pregnant women were found to have gut-
associated metabolites (odoribacter and butyrate) that inversely correlated with systolic blood pressure 
endothelial markers (plasminogen activator inhibitor 1), suggesting that the microbiome may influence blood 
pressure regulation in pregnancy.93 Future microbiome-related studies among obese pregnant women may 
prove beneficial in understanding the pathology of PEC and GDM, given the increased prevalence of obesity. 
 
Preterm birth 
The volume of microbiome studies seeking to identify bacterial communities associated with PTB is extensive. 
Researchers, utilizing descriptive and correlational studies, attempted to find microbial predictors of premature 
labor. While all the RCTs sought to reduce PTB risk,39,48,50 prevention and treatment of infections using probiotic 
interventions, particularly for BV, were important aims.36,49 Probiotics have been shown to be an effective 
independent or adjunctive therapy for BV.94 
 
Disparities in perinatal outcomes disproportionately impact African American women and their families. The 
findings of this scoping review suggest that the vaginal flora of African American women may predispose them 
to PTB risk. Customized nutritional interventions with prebiotics, probiotics, or synbiotics95 may offer low-risk 
strategies for primary prevention. 
 
Premature labor and birth are often the result of polymicrobial infection96 with organisms of vaginal origin.35 
Vaginal dysbiosis increases the risk of preterm premature rupture of the membranes and neonatal sepsis.61 
Based on the studies reviewed, these findings provide opportunities for effective prevention and/or intervention 
at the microbial level. Studies on microbial aspects of PTB prevention require adequate statistical power to 
demonstrate efficacy of interventions. 
 
Gestational diabetes 
Since GDM is nonacute and diagnosed at predictable intervals during pregnancy, it is compatible with 
prospective study. Thus, GDM has received considerable attention in RCTs of probiotic interventions. Healthy 
women were enrolled in 2 studies.46,47 Findings from both studies demonstrated that probiotic interventions 
reduced the incidence of GDM.46,47 The remaining RCTs used samples of women with GDM and focused on 
interventions with probiotics to improve metabolic outcomes. In contrast, there is a dearth of research on the 
microbiome associated with GDM. Since inflammation is associated with GDM, more research in this area is 
warranted. 
 
Although not detailed in this review, Bifidobacterium and Lactobacillus were the most studied species of 
probiotics in GDM RCTs. Probiotic strains and dosages varied greatly between studies. For example, 1 study used 
only 1 million colony-forming units of a single probiotic strain,44 while another used a multispecies probiotic with 
1 trillion colony-forming units.42 In their meta-analysis of probiotics and GDM, Zheng et al33 suggested that a 
probiotic dose of greater than 107 colony-forming units may lead to the most benefit. The authors concluded 
that antenatal probiotic interventions had a favorable effect on glucose metabolism.33 More well-controlled 
trials of the efficacy of various well-characterized probiotic strains and dosages on GDM diagnosis and metabolic 
outcomes are needed. 
Conclusions 
The role of the microbiome in PEC, PTB, and GDM is not fully elucidated, although findings from this review 
suggest that pathogenic microbes in a variety of habitats including the placenta, oral cavity, vagina, and gut may 
influence the risk for adverse pregnancy outcomes. Although distinct microbial profiles were not identified in 
select outcomes, probiotics appear to be effective in reducing the risk for PEC, PTB, and GDM in some cases. 
Probiotic interventions were not associated with adverse events and were well tolerated by the participants. In 
studies, all 3 entities covered in this review, PEC, GDM, and PTB, were associated with an increase in markers of 
systemic inflammation.4,54 Future studies investigating the role of the microbiome on a variety of inflammatory 
pathways may help elucidate biological pathways underpinning microbial dysbiosis. In addition, laboratory 
technologies used to study the metagenomics are complex and continually evolving.64 For example, the analyses 
can be expensive, time-consuming, and dependent on databases that are imperfect. Newer next-generation 
sequencing will likely improve accuracy.64 More research in this area in conjunction with advanced molecular 
sequencing technologies could significantly impact perinatal outcomes for women who experience any of these 
high-risk complications. 
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